All In Biotech

Drug Trial Radar · NCT07308041

A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin

An Open, Single Arm, Single-center, Phase 1 Trial Investigating the Effect of 7-days-repeated Administration of Linaprazan Glurate on the Pharmacokinetics of Repeated Doses of Amoxicillin in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Nov 11, 2025

Primary completion

Dec 22, 2025

Study completion Dec 22, 2025

Sponsor

Lead sponsor
Cinclus Pharma Holding ABIndustry
Sponsor type
Industry
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open, single arm, single-center Phase I trial designed to evaluate the effect of seven days repeated oral doses of linaprazan glurate on the pharmacokinetics (PK) of repeated doses of amoxicillin in healthy male and female participants

Conditions

  • Drug Interaction
  • GERD (Gastroesophageal Reflux Disease)
  • Safety, and Tolerability

Interventions

  • Drug Drug InteractionDrug

    The intervention phase consists of 2 periods: in period 1, the pharmacokinetics (PK) of amoxicillin will be evaluated in the absence of linaprazan glurate, in period 2, a potential effect of linaprazan glurate on the PK of amoxicillin will be evaluated as well as the PK of linaprazan glurate following co-administration of amoxicillin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterization of the PK of amoxicillin following a repeated dose before and after repeated administration of linaprazan glurate (AUC)Time frame: Day 1 and Day 8
  2. Characterization of the PK of amoxicillin following a repeated dose before and after repeated administration of linaprazan glurate (Cmax)Time frame: Day 1 and Day 8
  3. Characterization of the PK of amoxicillin following a repeated dose before and after repeated administration of linaprazan glurate (Tmax)Time frame: Day 1 and Day 8
  4. Characterization of the PK of amoxicillin following a repeated dose before and after repeated administration of linaprazan glurate (CL/F)Time frame: Day 1 and Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CTC Clinical Trial Consultants AB

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.